$52 Million

Evelo Biosciences

Follow-on Offering

Bookrunner, June 2020

Evelo Biosciences, Inc. is discovering and developing therapies designed to engage immune cells in the small intestine to drive therapeutic immune effects throughout the body for the treatment of inflammatory diseases and cancers. The action of its therapies is based upon the observation that immune cells in the small intestine have a central role in governing the immune, metabolic and neurological systems throughout the body. The Company’s monoclonal microbials are orally-delivered pharmaceutical compositions of naturally-occurring, specific single strains of microbes. Evelo currently has five product candidates: EDP1815, EDP1867, EDP2939 and EDP1632 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer.

More Like This

Jul 2020
$86 Million

Follow-on Offering

Lead Left Bookrunner

View Details
Jul 2020
$518 Million

Follow-on Offering

Bookrunner

View Details
Jun 2020
$69 Million

Follow-on Offering

Bookrunner

View Details